Novo Nordisk news

On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

On 15 August 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Novo Nordisk today announced clinical results from a 32-week open-label extension of a 20-week phase 2 obesity study, in which treatment with liraglutide, the once-daily human GLP-1 analogue, was tested in obese people without diabetes. Novo Nordisk reported headline results from the initial 20 weeks of the phase 2 study in November 2007.

At Novo Nordisk's ordinary general meeting on 12 March 2008 it was decided to reduce the company's B share capital from DKK 539,472,800 to DKK 526,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 12,960,000 divided into 12,960,000 B shares of DKK 1.

Novo Nordisk today announced the decision to discontinue the phase 3 clinical trial with NovoSeven® for the treatment of bleeding in patients with severe trauma. The decision was made based on the results of an analysis for futility conducted by the independent Data Monitoring Committee. The phase 3 trial was evaluating the efficacy and safety of NovoSeven® in severely injured trauma patients with bleeding refractory to standard treatment. The primary efficacy endpoint of the study was mortality and morbidity.

On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved PrandiMet(TM), a fixed-dose combination of the fast-acting insulin secretagogue repaglinide and metformin for the treatment of type 2 diabetes.

On 31 January 2008 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

As part of the execution of Novo Nordisk's current DKK 17.5 billion share repurchase programme expected to be finalised before the end of 2009, a repurchase programme is initiated today in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003 (Safe Harbour regulation).